CLINICAL TRIALS PROFILE FOR DUPILUMAB
✉ Email this page to a colleague
All Clinical Trials for Dupilumab
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01312961 ↗ | Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma | Completed | Regeneron Pharmaceuticals | Phase 2 | 2011-03-01 | Primary Objective: To investigate the effects of Dupilumab (SAR231893/REGN668) administered subcutaneously (SC) once weekly (qw) for 12 weeks as compared to placebo on reducing the incidence of asthma exacerbation in participants with persistent moderate to severe eosinophilic asthma. Secondary Objectives: - To assess the safety and tolerability of Dupilumab administered SC qw for 12 weeks in participants with persistent moderate to severe eosinophilic asthma. - To assess Dupilumab serum concentrations following qw SC dosing for 12 weeks in participants with persistent moderate to severe eosinophilic asthma. |
| NCT01312961 ↗ | Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma | Completed | Sanofi | Phase 2 | 2011-03-01 | Primary Objective: To investigate the effects of Dupilumab (SAR231893/REGN668) administered subcutaneously (SC) once weekly (qw) for 12 weeks as compared to placebo on reducing the incidence of asthma exacerbation in participants with persistent moderate to severe eosinophilic asthma. Secondary Objectives: - To assess the safety and tolerability of Dupilumab administered SC qw for 12 weeks in participants with persistent moderate to severe eosinophilic asthma. - To assess Dupilumab serum concentrations following qw SC dosing for 12 weeks in participants with persistent moderate to severe eosinophilic asthma. |
| NCT01385657 ↗ | Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis | Completed | Sanofi | Phase 1 | 2011-07-31 | The purpose of this study is to assess the safety and tolerability of repeated subcutaneous (SC) doses of Dupilumab in participants with moderate-to-severe atopic dermatitis (AD). |
| NCT01385657 ↗ | Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis | Completed | Regeneron Pharmaceuticals | Phase 1 | 2011-07-31 | The purpose of this study is to assess the safety and tolerability of repeated subcutaneous (SC) doses of Dupilumab in participants with moderate-to-severe atopic dermatitis (AD). |
| NCT01548404 ↗ | Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis | Completed | Sanofi | Phase 2 | 2012-04-01 | The primary objective was to assess the clinical efficacy of repeated subcutaneous (SC) doses of Dupilumab in adult participants with moderate-to-severe atopic dermatitis (AD). |
| NCT01548404 ↗ | Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis | Completed | Regeneron Pharmaceuticals | Phase 2 | 2012-04-01 | The primary objective was to assess the clinical efficacy of repeated subcutaneous (SC) doses of Dupilumab in adult participants with moderate-to-severe atopic dermatitis (AD). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Dupilumab
Condition Name
Clinical Trial Locations for Dupilumab
Trials by Country
Clinical Trial Progress for Dupilumab
Clinical Trial Phase
Clinical Trial Sponsors for Dupilumab
Sponsor Name
